Replies to post #99 on Abbott Laboratories (ABT)

[DewDiligence]

ABT ‘ReadMeFirst’ updated:

Elagolix starts phase-2 in uterine fibroids;
economic terms of Elagolix partnership with NBIX;
FDA approves companion diagnostic for PFE’s Xalkori;
testing of Absorb begins in critical limb ischemia;
new musings on competitive threat to Humira from PFE’s Tofacitinib.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=67058123